Other studies have shown that interleukin-17A can cause MASH and HCC, while interleukin-17A inhibitors can prevent MASH and HCC in high-risk patients (102) (Figure 2G). Here, IL17A is linked to metabolic dysfunction-associated steatohepatitis.